US 12,280,073 B2
Bi-functional co-polymer use for ophthalmic and other topical and local applications
Eugene Rex Cooper, Berwyn, PA (US); David Maxwell Kleinman, Rochester, NY (US); Andrew Loxley, Philadelphia, PA (US); and Mark A. Mitchnick, East Hampton, NY (US)
Assigned to Calm Water Therapeutics LLC, Rochester, NY (US)
Filed by Calm Water Therapeutics LLC, Rochester, NY (US)
Filed on Jul. 17, 2023, as Appl. No. 18/222,690.
Application 16/940,231 is a division of application No. 15/889,493, filed on Feb. 6, 2018, granted, now 10,729,715, issued on Aug. 4, 2020.
Application 15/889,493 is a division of application No. 15/069,188, filed on Mar. 14, 2016, granted, now 9,884,074, issued on Feb. 6, 2018.
Application 18/222,690 is a continuation of application No. 17/463,797, filed on Sep. 1, 2021, abandoned.
Application 17/463,797 is a continuation of application No. 16/940,231, filed on Jul. 27, 2020, granted, now 11,110,119, issued on Sep. 7, 2021.
Application 15/069,188 is a continuation of application No. 14/661,804, filed on Mar. 18, 2015, granted, now 9,283,248, issued on Mar. 15, 2016.
Application 14/661,804 is a continuation of application No. 14/328,484, filed on Jul. 10, 2014, granted, now 9,005,596, issued on Apr. 14, 2015.
Application 14/328,484 is a continuation of application No. 12/708,329, filed on Feb. 18, 2010, granted, now 8,802,075, issued on Aug. 12, 2014.
Claims priority of provisional application 61/153,416, filed on Feb. 18, 2009.
Prior Publication US 2023/0355661 A1, Nov. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/785 (2006.01); A61K 9/00 (2006.01); A61K 9/50 (2006.01); A61K 9/51 (2006.01); A61K 31/045 (2006.01); A61K 31/7036 (2006.01); A61K 31/74 (2006.01); A61K 31/765 (2006.01); A61K 35/02 (2015.01); A61K 45/06 (2006.01); A61K 47/34 (2017.01); G02C 7/04 (2006.01)
CPC A61K 31/785 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0043 (2013.01); A61K 9/0048 (2013.01); A61K 9/0051 (2013.01); A61K 9/0073 (2013.01); A61K 9/5031 (2013.01); A61K 9/5146 (2013.01); A61K 31/045 (2013.01); A61K 31/7036 (2013.01); A61K 31/74 (2013.01); A61K 31/765 (2013.01); A61K 35/02 (2013.01); A61K 45/06 (2013.01); A61K 47/34 (2013.01); G02C 7/04 (2013.01)] 4 Claims
 
1. A method of treating an ophthalmic disease or condition in a subject, comprising topically administering to an ocular surface of said subject a composition comprising a graft copolymer comprising:
(i) a positively charged backbone, wherein the positively charged backbone is
selected from the group consisting of poly(2-vinyl pyridine), poly(4-vinyl pyridine) and vinyl co-polymers thereof, and
(ii) one or more hydrophilic water soluble side chains selected from the group consisting of polyethylene glycols, polysaccharides, poly(meth)acrylates, polyacrylamides, polyvinyl alcohol (PVA), polyethyloxazoline, poly-N-vinyl pyrrolidone (NVP) and poly boronic-based polymers;
in an amount and for a duration so as to prolong the stability of the tear film of said subject.